410957
3-Isobutyl-1-methylxanthine
≥98% (HPLC), solid, cAMP and cGMP phosphodiesterase inhibitor, Calbiochem®
Synonyme(s) :
3-Isobutyl-1-methylxanthine, IBMX
Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
About This Item
Formule empirique (notation de Hill):
C10H14N4O2
Numéro CAS:
Poids moléculaire :
222.24
Numéro MDL:
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.77
Produits recommandés
product name
3-Isobutyl-1-methylxanthine, A cell-permeable, non-specific inhibitor of cAMP and cGMP phosphodiesterases (IC₅₀ = 2-50 µM).
Niveau de qualité
Pureté
≥98% (HPLC)
Forme
solid
Fabricant/nom de marque
Calbiochem®
Conditions de stockage
OK to freeze
Couleur
white
Solubilité
ethanol: 10 mg/mL
DMSO: 100 mM
methanol: 50 mg/mL
Conditions d'expédition
ambient
Température de stockage
−20°C
InChI
1S/C10H14N4O2/c1-6(2)4-14-8-7(11-5-12-8)9(15)13(3)10(14)16/h5-6H,4H2,1-3H3,(H,11,12)
Clé InChI
APIXJSLKIYYUKG-UHFFFAOYSA-N
Description générale
A cell-permeable, non-specific inhibitor of cAMP and cGMP phosphodiesterases (IC50 = 2-50 µM). Also acts as an adenosine receptor antagonist. Reported to inhibit TNF-α expression in adipocyte precursor cells.
A non-specific, cell-permeable inhibitor of cAMP and cGMP phosphodiesterases (IC50 = 2-50 µM). Also acts as an adenosine receptor antagonist. Reported to inhibit TNFα expression in adipocyte precursor cells.
Actions biochimiques/physiologiques
Cell permeable: yes
Primary Target
cAMP and cGMP phosphodiesterases
cAMP and cGMP phosphodiesterases
Product does not compete with ATP.
Reversible: no
Target IC50: 2-50 µM against cAMP and cGMP phosphodiesterases
Avertissement
Toxicity: Standard Handling (A)
Notes préparatoires
Heating may be required to achieve complete solubilization.
Reconstitution
Following reconstitution in ethanol or methanol, refrigerate (4°C). Following reconstitution in DMSO, aliquot and freeze (-20°C). Ethanol/methanol and DMSO stock solutions are stable for up to 6 months at 4°C or -20°C, respectively.
Autres remarques
Hube, F., et al. 1999. Horm. Metab. Res.31, 359.
Morgan, A.J., et al. 1993. Biochem. Pharmacol.45, 2373.
Scamps, F., et al. 1993. Eur. J. Pharmacol. 244, 119.
Turner, N.C., et al. 1993. Br. J. Pharmacol. 108, 876.
Tamura, T., et al. 1991. J. Gen. Physiol. 98, 95.
Beavo, J.A., and Reifsnyder, D.H. 1990. Trends Pharmacol. Sci.11, 150.
Russell, T.R. 1979. Proc. Natl. Acad. Sci. USA76, 4451.
Morgan, A.J., et al. 1993. Biochem. Pharmacol.45, 2373.
Scamps, F., et al. 1993. Eur. J. Pharmacol. 244, 119.
Turner, N.C., et al. 1993. Br. J. Pharmacol. 108, 876.
Tamura, T., et al. 1991. J. Gen. Physiol. 98, 95.
Beavo, J.A., and Reifsnyder, D.H. 1990. Trends Pharmacol. Sci.11, 150.
Russell, T.R. 1979. Proc. Natl. Acad. Sci. USA76, 4451.
Informations légales
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Code de la classe de stockage
11 - Combustible Solids
Classe de danger pour l'eau (WGK)
WGK 3
Point d'éclair (°F)
Not applicable
Point d'éclair (°C)
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Les clients ont également consulté
Jiang Li et al.
Antioxidants (Basel, Switzerland), 13(5) (2024-05-25)
Hypertension reduces the bioavailability of vascular nitric oxide (NO) and contributes to the onset of vascular dementia (VaD). A loss of NO bioavailability increases inflammation and oxidative stress. 2-(4-Methylthiazol-5-yl) ethyl nitrate hydrochloride (W1302) is a novel nitric oxide donor (NOD)
Jiankun Xu et al.
Bioactive materials, 8, 95-108 (2021-09-21)
Magnesium metal and its alloys are being developed as effective orthopedic implants; however, the mechanisms underlying the actions of magnesium on bones remain unclear. Cystic fibrosis, the most common genetic disease in Caucasians caused by the mutation of CFTR, has
Dina Hany et al.
Science advances, 9(19), eadd3685-eadd3685 (2023-05-12)
In breast cancer, resistance to endocrine therapies that target estrogen receptor α (ERα), such as tamoxifen and fulvestrant, remains a major clinical problem. Whether and how ERα+ breast cancers switch from being estrogen-dependent to estrogen-independent remains unclear. With a genome-wide
H Ji
Methods in molecular medicine, 51, 363-377 (2001-01-01)
Angiotensin type-1 receptors (AT(1) receptors) mediate various physiological actions of angiotensin (Ang II) via multiple-signal transduction pathways (1). In addition to the phospholipase C pathway and dihydropyridine-sensitive voltage-dependent calcium channels, AT(1) receptors can couple to inhibition of adenylate cyclase via
Salaheldeen Elsaid et al.
FEBS open bio, 14(8), 1277-1290 (2024-06-26)
In multicellular organisms, stem cells are impacted by microenvironmental resources such as nutrient availability and oxygen tension for their survival, growth, and differentiation. However, the accessibility of these resources in the pericellular environment greatly varies from organ to organ. This
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique